The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis.

Zhou Q, Yin S, Lei X, Tian Y, Lin D, Wang L, Chen Q

Diabetology & metabolic syndrome19 Aug 2024Cited by 8 (Europe PMC)

PMID39160573PMCIDPMC11331736DOI10.1186/s13098-024-01405-wPepBankPUB-39160573

Summary

BackgroundMOTS-c is known as mitochondrial open reading frame (ORF) of the twelve S c, produced by a small ORF-encoded peptides (SEPs) in mitochondrial 12S rRNA region. There is growing evidence that MOTS-c has a strong relationship with the expression of inflammation- and metabolism-associated genes and metabolic homeostasis, and even offering some protection against insulin resistance (IR). However, studies have reported inconsistent correlations between different population characteristics and MOTS-c levels. This meta-analysis aims to elucidate MOTS-c levels in physiological and pathological states, and its correlation with metabolic features in various physiological states.MethodsWe conducted a systematic review and meta-analysis to synthesize the evidence of changes in blood MOTS-c concentration, and any association between MOTS-c and population characteristic. The Web of Science, PubMed, EMBASE, CNKI, WANGFANG and VIP databases were searched from inception to April 2023. The statistical analysis was summarized using the standardized mean difference (SMD) and 95% confidence interval (95% CIs). Pearson correlation coefficient was used to analyze the correlation and generate forest plots through a random-effects model. Additional analyses as sensitivity and subgroup analyses were performed to identify the origins of heterogeneity. Publication bias was retrieved by means of a funnel-plot analysis and Egger's test. All related statistical analyses were performed using Revman 5.3 and Stata 15 statistical software.ResultThere are 6 case-control studies and 1 cross-sectional study (11 groups) including 602 participants in our current meta-analysis. Overall analysis results showed plasma MOTS-c concentration in diabetes and obesity patients was significantly reduced (SMD = - 0.37; 95% CI- 0.53 to - 0.20; P < 0.05). After subgroup analysis, the present analysis has yielded opposite results for MOTS-c changes in obesity (SMD = 0.51; 95% CI 0.21 to 0.81; P < 0.05) and type 2 diabetes mellitus (T2DM) (SMD = - 0.89; 95% CI - 1.12 to - 0.65; P < 0.05) individuals. Moreover, the correlation analysis was performed to identify that MOTS-c levels were significantly positively correlated with TC (r = 0.29, 95% CI 0.20 to 0.38) and LDL-c (r = 0.30, 95% CI 0.22 to 0.39). The subgroup analysis results showed that MOTS-c decreased significantly in patients with diabetes (SMD = - 0.89; 95% CI- 1.12 to - 0.65; P < 0.05). In contrast, the analysis result for obesity persons (BMI > 28 kg/ m²) was statistically significant after overweight people (BMI = 24-28 kg/ m²) were excluded (SMD = 0.51; 95% CI 0.21 to 0.81; P < 0.05), which is completely different from that of diabetes. Publication bias was insignificant (Egger's test: P = 0.722).ConclusionCirculating MOTS-c level was significantly reduced in diabetic individuals but was increased significantly in obesity patients. The application of monitoring the circulating levels variability of MOTS-c in routine screening for obesity and diabetes is prospects and should be taken into consideration as an important index for the early prediction and prevention of metabolic syndrome in the future. PROSPERO registration number CRD42021248167.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelSystematic reviewOther
In a meta-analysis of case-control and cross-sectional studies, plasma MOTS‑c concentration was significantly lower in patients with diabetes and obesity combined than in comparison groups.
In plain wordsIn people with diabetes and obesity combined, the body's own MOTS‑c level in blood was lower in a pooled analysis of studies.
Peptide
MOTS-c
Outcome
DecreasePlasma MOTS-c in diabetes and obesity patients combined
Study
n = 602
Outcome group
Aging markers · Metabolic and weight
Measurements
SMD
−0.37 SD
diabetes and obesity combined
Source sentences
Summary
Overall analysis results showed plasma MOTS-c concentration in diabetes and obesity patients was significantly reduced (SMD = - 0.37; 95% CI- 0.53 to - 0.20; P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
There are 6 case-control studies and 1 cross-sectional study (11 groups) including 602 participants in our current meta-analysis.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3916057301
02HumanEndogenous levelSystematic reviewOther
In the obesity subgroup of a meta-analysis, plasma MOTS‑c concentration was significantly higher than in comparison groups.
In plain wordsIn people with obesity, the body's own MOTS‑c level in blood was higher in a pooled analysis of studies.
Peptide
MOTS-c
Outcome
IncreasePlasma MOTS-c in obesity
Study
n: not reported in source
Outcome group
Aging markers · Metabolic and weight
Measurements
SMD
0.51 SD
obesity
Source sentences
Summary
the present analysis has yielded opposite results for MOTS-c changes in obesity (SMD = 0.51; 95% CI 0.21 to 0.81; P < 0.05) and
2 context sentences(design, population, supporting numbers)
Summary · context
In contrast, the analysis result for obesity persons (BMI > 28 kg/ m²) was statistically significant after overweight people (BMI = 24-28 kg/ m²) were excluded (SMD = 0.51; 95% CI 0.21 to 0.81; P < 0.05), which is completely different from that of diabetes.
Summary · context
There are 6 case-control studies and 1 cross-sectional study (11 groups) including 602 participants in our current meta-analysis.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3916057302
03HumanEndogenous levelSystematic reviewOther
In the type 2 diabetes subgroup of a meta-analysis, plasma MOTS‑c concentration was significantly lower than in comparison groups.
In plain wordsIn people with type 2 diabetes, the body's own MOTS‑c level in blood was lower in a pooled analysis of studies.
Peptide
MOTS-c
Outcome
DecreasePlasma MOTS-c in type 2 diabetes
Study
n: not reported in source
Outcome group
Aging markers · Metabolic and weight
Measurements
SMD
−0.89 SD
type 2 diabetes
Source sentences
Summary
The subgroup analysis results showed that MOTS-c decreased significantly in patients with diabetes (SMD = - 0.89; 95% CI- 1.12 to - 0.65; P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
There are 6 case-control studies and 1 cross-sectional study (11 groups) including 602 participants in our current meta-analysis.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3916057303
04HumanEndogenous levelSystematic reviewOther
In a meta-analysis, circulating MOTS‑c levels were positively correlated with total cholesterol.
In plain wordsHigher body's own MOTS‑c levels were linked to higher total cholesterol in a pooled analysis of studies.
Peptide
MOTS-c
Outcome
IncreaseCorrelation of MOTS-c with total cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Measurements
Pearson r
0.29
total cholesterol
Source sentences
Summary
MOTS-c levels were significantly positively correlated with TC (r = 0.29, 95% CI 0.20 to 0.38)
1 context sentence(design, population, supporting numbers)
Summary · context
There are 6 case-control studies and 1 cross-sectional study (11 groups) including 602 participants in our current meta-analysis.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3916057304
05HumanEndogenous levelSystematic reviewOther
In a meta-analysis, circulating MOTS‑c levels were positively correlated with LDL cholesterol.
In plain wordsHigher body's own MOTS‑c levels were linked to higher LDL cholesterol in a pooled analysis of studies.
Peptide
MOTS-c
Outcome
IncreaseCorrelation of MOTS-c with LDL-c
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Measurements
Pearson r
0.3
LDL-c
Source sentences
Summary
MOTS-c levels were significantly positively correlated with TC (r = 0.29, 95% CI 0.20 to 0.38) and LDL-c (r = 0.30, 95% CI 0.22 to 0.39).
1 context sentence(design, population, supporting numbers)
Summary · context
There are 6 case-control studies and 1 cross-sectional study (11 groups) including 602 participants in our current meta-analysis.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3916057305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.